widerrufen.
23.12 15:30
30 Min
Medical Frontiers
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 percent of patients. We interview Japanese researchers who are trying to overcome this challenge. ()
23.12 15:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JAPAN)
23.12 15:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JPN)
23.12 15:30
30 Min
Medical Frontiers
ICIs : Key to Surviving Cancer (NHK WORLD)
23.12 21:30
30 Min
Medical Frontiers
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 percent of patients. We interview Japanese researchers who are trying to overcome this challenge. ()
23.12 21:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JAPAN)
23.12 21:30
30 Min
Medical Frontiers
ICIs : Key to Surviving Cancer (NHK WORLD)
23.12 21:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JPN)
24.12 04:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JAPAN)
24.12 04:30
30 Min
Medical Frontiers: 2050-160
While immune checkpoint inhibitors can improve cancer survival rates, they only work in about 20 to 30 per cent of patients - we interview Japanese researchers trying to overcome this challenge. (NHK WORLD-JPN)